Beta3-adrenoreceptor agonist mirabegron – a potential antiobesity drug?

Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade

(2016) E C Alexandre et al.   BRITISH JOURNAL OF PHARMACOLOGY

Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females

(2016) Jan Krhut et al.   European Journal of Obstetrics & Gynecology and Reproductive Biology

Genotype-Dependent Brown Adipose Tissue Activation in Patients With Pheochromocytoma and Paraganglioma

(2016) Troy Puar et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia

(2016) Keyvan Karimi Galougahi et al.   Journal of the American Heart Association

Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist

(2015) Aaron M. Cypess et al.   Cell Metabolism

Induction of thermogenesis in brown and beige adipose tissues

(2015) Andrew C. McMillan et al.   Current Opinion in Endocrinology Diabetes and Obesity

Temperature-Acclimated Brown Adipose Tissue Modulates Insulin Sensitivity in Humans

(2014) Paul Lee et al.   DIABETES

Overview of new antiobesity drugs

(2014) Vojtech Hainer   EXPERT OPINION ON PHARMACOTHERAPY

Mirabegron in the treatment of overactive bladder

(2014) Umberto Leone Roberti Maggiore et al.   EXPERT OPINION ON PHARMACOTHERAPY

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies

(2013) V. W. Nitti et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Brown and beige fat: development, function and therapeutic potential

(2013) Matthew Harms et al.   NATURE MEDICINE

Proarrhythmic Safety of Repeat Doses of Mirabegron in Healthy Subjects: A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study

(2012) M Malik et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive Bladder

(2012) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Challenges in β3-adrenoceptor agonist drug development

(2011) Jonathan R. S. Arch   Therapeutic Advances in Endocrinology and Metabolism

Cold-Activated Brown Adipose Tissue in Healthy Men

(2009) Wouter D. van Marken Lichtenbelt et al.   NEW ENGLAND JOURNAL OF MEDICINE